Navigation Links
Anti-Cancer Drug CYT997 Update
Date:3/12/2008

MELBOURNE, Australia, March 12 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) has commenced dosing patients in the first of a suite of Phase II clinical studies for its vascular disrupting agent (VDA), CYT997. These studies will investigate the activity of this anti-cancer compound in specific cancer types with high unmet medical need and poor prognoses.

VDAs are a new class of drugs to treat cancer and have potential for "blockbuster" sales in the treatment of vascularized tumors. CYT997 has a dual mechanism of action shutting down established blood vessels that supply the tumor with nutrients and oxygen and also direct cytotoxic properties. Capable of being delivered orally as well as intravenously, the compound was discovered by Cytopia scientists in 2003 and an Investigational New Drug application was accepted by the US Food and Drug Administration in 2005 to commence Phase I studies.
During the 2008 financial year Cytopia has:

-- commenced dosing in its first Phase II study

-- finalized preparations for its second Phase II study

-- concluded its first Phase I safety and tolerability study with

intravenous administration

-- continued dose-escalation in its Phase I capsule dosing study (oral

administration)

Phase II clinical programs

1. Phase II trial in multiple myeloma Cytopia commenced dosing in its first Phase II efficacy study in patients with relapsed or refractory multiple myeloma in January 2008, some four months after conclusion of its initial Phase I study. The Phase II study is a two- stage design with an interim clinical activity analysis after 14 patients and maximum enrolment of 24 patients. Enrolment into this efficacy study is progressing on schedule and Cytopia anticipates undertaking interim data analysis by September this year.

This clinical study follows an extensive body of preclinical studies, including studies in cells from heavily pre-tr
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
2. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
5. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
6. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
7. Treatment of First Patient in Phase I Clinical Trial of Bionomics Anti-Cancer Drug BNC105
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/10/2014)... more likely to be diagnosed with more aggressive ... for shorter times than prostate cancer patients who ... , The negative outcomes may be the result ... mentally ill, depression,s impact on biological cancer processes, ... general health and disinterest in receiving more effective ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to talk ... their silent suffering if they are willing to ... Baylor University case study., After seven weeks of hypnotic ... flashes following prostate cancer surgery showed a drastic decrease ... improvement in sleep quality, according to the study., The ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... Cancer Center paint a relatively optimistic picture of women,s ... have spread to the chest wall or skin, but ... skin, regardless of size and whether they have involved ... and called "locally advanced" tumors, suggesting that they are ... survival. Locally advanced breast cancers of this and other ...
Breaking Medicine News(10 mins):Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Urban Aboriginal people face unique health challenges 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3
... , , , ... a contribution of up to $81.4 million to the Healthy Families Program ... children at risk of losing coverage due to the state,s fiscal crisis. ... be used to cover children ages 0-5 through June 2010. , ...
... studies find types of hormones used raise or lower ... The composition of a woman,s contraceptive pill influences her ... lung, European researchers say. , Scientists have long known ... and progestogen, increase the likelihood of deep vein thrombosis ...
... , , EDINA, Minn., Aug. 13 ... best interest of patients as a key focal point. We do ... and credit card fraud recently announced in the news. The MCA ... protect the public interest in this unfortunate situation. , ...
... , , , ... regarding changes to Mississippi Medicaid benefits for speech therapy services, The ... Mississippi Division of Medicaid on the new Medicaid claiming policy for ... for speech therapy services provided by school providers, which are in ...
... , , DEERFIELD, Ill., Aug. ... supplier of protective packaging products and specialty packaging solutions, today ... , For the second quarter of 2009, ... of 28.8% versus net sales of $275.2 million in the ...
... SANTA FE, N.M., Aug. 13 The New Mexico ... new alliance to assist school districts with Medicaid claiming. This program ... will be administered by Accelify. , , "We ... Executive Director. "NMSBA is focused on bringing value-added programs to New ...
Cached Medicine News:Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Some Birth Control Pills Safer Than Others 2Health News:Some Birth Control Pills Safer Than Others 3Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 2Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 3Health News:Pregis Announces Second Quarter 2009 Financial Results 2Health News:Pregis Announces Second Quarter 2009 Financial Results 3Health News:Pregis Announces Second Quarter 2009 Financial Results 4Health News:Pregis Announces Second Quarter 2009 Financial Results 5Health News:Pregis Announces Second Quarter 2009 Financial Results 6Health News:Pregis Announces Second Quarter 2009 Financial Results 7Health News:Pregis Announces Second Quarter 2009 Financial Results 8Health News:Pregis Announces Second Quarter 2009 Financial Results 9Health News:Pregis Announces Second Quarter 2009 Financial Results 10Health News:Pregis Announces Second Quarter 2009 Financial Results 11Health News:Pregis Announces Second Quarter 2009 Financial Results 12Health News:Pregis Announces Second Quarter 2009 Financial Results 13Health News:Pregis Announces Second Quarter 2009 Financial Results 14Health News:Pregis Announces Second Quarter 2009 Financial Results 15Health News:New Mexico School Boards Association and Accelify Announce Alliance to Assist New Mexico Schools 2
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
Steroid eluting pacemaker leads...
... Medtronic presents the Streamline family of temporary ... taken the gold standard in temporary pacing ... make them easy to use and less ... 6491 Unipolar Pediatric Temporary Pacing Lead is ...
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
Medicine Products: